Clinical Trial Search

Primary: Area Under the Curve 0-72 h (Deuterium Labeled Alpha-tocopherol) — 103; 115; 102; 102 umol/L x h

Primary: Overall Response Rate (ORR) Based on Independent Radiological Review (IRR) — 35 percentage of participants

Primary: Number of Participants With Adverse Drug Reactions — 1; 1; 1; 2 participants

Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…

Primary: Percentage of Participants With Best Overall Response (BOR) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…

Primary: Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies — 100.0; 99.5; 98.7; 97.3 percentage of…

Primary: Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity. — 0; 3; 3; 2 participants

Primary: Percentage of Subjects With Hypercalcemia — 15.3 percentage of participants

Primary: Percentage of Participants Who Achieve Sustained Virological Response at Follow-up Week 24 (SVR24) — 35.2 Percentage of participants

Primary: Change in Modified Oswestry Low Back Pain Disability Index — -8.25; -0.86 units on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Adverse Reactions — 343; 207 participants

Primary: Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin — 24.8; 48.4; 118 ng/mL

Primary: Change in Muscle Sympathetic Nerve Activity in Bursts Per 100 Heartbeats — 59; 45 bursts/100 heartbeats — p=<0.05

Primary: Progression-Free Survival (PFS) — 73 percentage of participants

Primary: Maximum Dose of Levodopa/Carbidopa That Can be Tolerated (Without Any Dose Limiting Toxicity) by at Least 3 Subjects. — 15 mg/kg/day